Truist Financial’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-3,244
Closed -$261K 2789
2025
Q4
$261K Buy
+3,244
New +$272K ﹤0.01% 2427
2024
Q4
Sell
-4,553
Closed -$477K 2511
2024
Q3
$477K Sell
4,553
-178
-4% -$20.8K ﹤0.01% 1897
2024
Q2
$673K Buy
+4,731
New +$545K ﹤0.01% 1803
2023
Q4
Sell
-3,360
Closed -$548K 2630
2023
Q3
$548K Sell
3,360
-1,267
-27% -$223K ﹤0.01% 1876
2023
Q2
$848K Sell
4,627
-4,094
-47% -$589K ﹤0.01% 1665
2023
Q1
$1.16M Sell
8,721
-12
-0.1% -$1.41K ﹤0.01% 1485
2022
Q4
$693K Buy
+8,733
New +$615K ﹤0.01% 1744
2022
Q3
Sell
-6,704
Closed -$368K 2511
2022
Q2
$368K Buy
+6,704
New +$388K ﹤0.01% 2094

Other funds holding ACLS

Truist Financial's ACLS Position: Q1 2026 in Review

Truist Financial sold out of Axcelis (ACLS) in Q1 2026, closing a stake of 3,244 shares — an estimated $261K sold.

Truist Financial first reported a position in ACLS in Q2 2022 and held it in 8 quarters. The position peaked at $1.16M in Q1 2023. 377 funds tracked by Wall St. Rank hold ACLS as of Q1 2026.

  • Truist Financial reported no remaining Axcelis position as of Q1 2026 after selling out during the quarter.
  • Truist Financial sold 3,244 Axcelis shares in Q1 2026, an estimated $261K.
  • Truist Financial first reported a position in Axcelis in Q2 2022 and held it in 8 quarters.
  • Truist Financial's Axcelis position peaked at $1.16M in Q1 2023.
  • 377 funds tracked by Wall St. Rank held Axcelis as of Q1 2026.

Based on Truist Financial's 13F filing for Q1 2026, filed 27 Apr 2026.